BGF World Healthscience D5
Pricing frequency
Daily
Dealing cut off time
–
Type
SICAV
Yield
0.26%
NAV
£17.33
Income frequency
Quarterly
Ongoing charge
1.06%
Latest actual NAV date
16-11-2026
ISIN
LU2112292763
UCITS
Yes
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 31/10/2026 | % of assets |
|---|---|
| Eli Lilly and Co | 10.73 |
| AbbVie Inc | 6.81 |
| Johnson & Johnson | 6.76 |
| Merck & Co Inc | 5.64 |
| Roche Holding AG Ordinary Shares new | 5.29 |
| Gilead Sciences Inc | 4.48 |
| Thermo Fisher Scientific Inc | 3.96 |
| UnitedHealth Group Inc | 3.91 |
| Amgen Inc | 3.38 |
| Novartis AG Registered Shares | 3.29 |
Investment objective
The Fund seeks to maximise total return and invest in a manner consistent with the principles of environmental, social and governance (“ESG”) investing. The Fund invests globally at least 70% of its total assets in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. Currency exposure is flexibly managed.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.